Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of asarone in preparation of medicine for treating or preventing cerebral infarction hemorrhage transformation

A technology for cerebral infarction and asarum, applied in the field of biomedicine, to reduce nerve damage, extend the treatment time window, and reduce mortality

Pending Publication Date: 2022-02-08
SICHUAN UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] In order to overcome the problem that there is no effective treatment or prevention of cerebral infarction hemorrhage transformation medicine in the prior art, the present invention provides a new application of α-asarone in the preparation of treatment or prevention of cerebral infarction hemorrhage transformation medicine

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of asarone in preparation of medicine for treating or preventing cerebral infarction hemorrhage transformation
  • Application of asarone in preparation of medicine for treating or preventing cerebral infarction hemorrhage transformation
  • Application of asarone in preparation of medicine for treating or preventing cerebral infarction hemorrhage transformation

Examples

Experimental program
Comparison scheme
Effect test

preparation Embodiment 1

[0080] Preparation Example 1 Preparation of α-Asarone Injection Emulsion

[0081] Weigh 0.50~50.0g of α-asarone and 50.0~300.0g of soybean oil for injection, put them in a suitable container, heat to 60~80℃ under the protection of nitrogen gas, stir to dissolve; continue to weigh egg yolk lecithin 6.0 ~18.0g, add it, stir to dissolve (if necessary, add 0.10~0.50g of oleic acid, sodium oleate or a mixture of the two), and obtain the oil phase, set aside. In addition, weigh 0~3.0g of Pluronic (F68), 0~25.0g of glycerin, measure about 800mL of water, heat to 60~80℃ under the protection of nitrogen gas, stir to dissolve, and obtain the water phase. Add the above oil phase to the water phase, shear at high speed for 5-15 minutes, add water to 1000mL, and prepare colostrum. Continue to homogenize the colostrum with a high-pressure homogenizer for 1 to 3 times, so that the average particle size of the milk droplets after homogenization is not greater than 0.5 μm, filter through a me...

preparation Embodiment 2

[0082] Preparation Example 2 Preparation of α-Asarone Injection Emulsion

[0083] Weigh 10.0 g of α-asarone, 50.0 g of soybean oil for injection, and 50.0 g of medium-chain triglyceride (MCT) for injection, put them in a suitable container, heat to 60-80°C under nitrogen protection, and stir to make Dissolving; continue to weigh 12.0 g of egg yolk lecithin and 0.3 g of sodium oleate, add them, stir to dissolve, and obtain an oil phase, which is set aside. Separately weigh 22.0 g of glycerin, measure about 800 mL of water, heat to 60-80 °C under the protection of nitrogen gas, stir to dissolve, and obtain the water phase. Add the above oil phase to the water phase, shear at high speed for 5-15 minutes, add water to 1000mL, and prepare colostrum. Continue to homogenize the colostrum with a high-pressure homogenizer for 1 to 3 times, so that the average particle size of the milk droplets after homogenization is not greater than 0.5 μm, filter the membrane, and fill the filtrate ...

preparation Embodiment 3

[0084] Preparation Example 3 Preparation of α-Asarone Injection Emulsion

[0085] Weigh 20.0 g of α-asarone, 100.0 g of soybean oil for injection, and 100.0 g of medium-chain triglyceride (MCT) for injection, put them in a suitable container, heat to 60-80°C under nitrogen protection, and stir to make Dissolving; continue to weigh 12.0 g of egg yolk lecithin and 0.3 g of oleic acid, add it, stir to dissolve, and obtain an oil phase for later use. Separately weigh 22.0g of glycerin, measure about 800mL of water, heat to 60~80°C under the protection of nitrogen gas, and stir to dissolve; the aqueous phase is obtained. Add the above oil phase to the water phase, shear at high speed for 5-15 minutes, add water to 1000mL, and prepare colostrum. Continue to homogenize the colostrum with a high-pressure homogenizer for 1 to 3 times, so that the average particle size of the milk droplets after homogenization is not greater than 0.5 μm, filter the membrane, and fill the filtrate into ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
wavelengthaaaaaaaaaa
Login to View More

Abstract

The invention relates to the technical field of medicines, in particular to a novel application of alpha-asarone in preparation of a medicine for treating or preventing cerebral infarction hemorrhage transformation, and particularly relates to a novel application of alpha-asarone in preparation of a medicine for treating or preventing cerebral infarction hemorrhage transformation caused by thrombolytic therapy. The alpha-asarone can inhibit the current of the voltage-gated sodium ion channel, and can selectively act on the inactivated sodium ion channel and prolong the reactivation time of the sodium ion channel. Accordingly, it is found that alpha-asarone can significantly improve the neurological function score of a cerebral infarction hemorrhage transformation model rat, reduce the cerebral infarction volume, relieve encephaledema and improve blood-brain barrier permeability (reduce the content of Evans blue in brain tissue), and therefore nerve injury caused by cerebral infarction hemorrhage transformation is relieved. The clinical use of alpha-asarone is expected to be helpful for improving the prognosis of a cerebral apoplexy patient and prolonging the thrombolysis treatment time window of the cerebral apoplexy patient; the nerve injury of cerebral apoplexy patients is relieved, the death rate is reduced, and the life quality is improved.

Description

technical field [0001] The invention belongs to the field of biomedicine, and mainly relates to the application of α-asarone in the preparation of hemorrhage conversion medicine for the treatment or prevention of cerebral infarction, especially the application of α-asarone in the preparation of treatment or prevention of hemorrhage caused by thrombolytic treatment of cerebral infarction Applications in translational medicine. Background technique [0002] Stroke is an acute cerebrovascular disease, which has surpassed malignant tumors and cardiovascular diseases and has become the first cause of death and disability among Chinese residents. It has the characteristics of high morbidity, high mortality, high disability rate and high recurrence rate. The latest epidemiological survey shows that the incidence of stroke is increasing rapidly at an average annual rate of 8.7%. Stroke is divided into ischemic stroke and hemorrhagic stroke. The former, also known as cerebral infar...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/09A61K9/107A61P9/10A61P25/00A61P7/10A61P7/04
CPCA61K31/09A61K9/0019A61K9/0053A61K9/107A61P9/10A61P25/00A61P7/10A61P7/04
Inventor 毛声俊罗丽君张迪高小凤胡钦蕊刘琪张检
Owner SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com